UroGen’s shares drop 20% as the FDA raises concerns about the trial design for UGN-102 bladder cancer treatment.

DICK'S Sporting Goods, Inc.'s $2.4B Foot Locker, Inc. acquisition raises concerns over strategy shifts. Click for my look at ...

Synopsys will present its results for the second quarter of 2025 on May 28 after the market closes. See why I think SNPS ...

Both Nebius and CoreWeave are neoclouds seeking to satiate the strong global demand for AI compute. Read more about why NBIS ...

NUTX delivered another quarter of strong earnings, driven by arbitration revenue and improved base operations.

Yelp thrives with strong fundamentals, double-digit home services growth, and attractive valuation. Read more here.

Explore why TEGNA Inc. remains a Strong Buy with solid cash flow, cost cuts, M&A potential, and double-digit returns despite ...

CoreWeave has seen impressive growth in the first quarter of 2025, comforting after a tough public offering. While growth is ...

BSY's Q1 results were strong, with accelerating revenue growth, solid subscription momentum, and key growth levers like E365 ...

Acadia Pharmaceuticals ( NASDAQ: ACAD) soared 20% after a court ruling in patent suit regarding its drug Nuplazid, which is ...

Maple Leaf shares are attractively priced, and the firm has a catalyst in the form of its pending spinoff. Read why I rate ...